Clinical Trial Update: Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients [Phase 1]

View source ↗

Summary

Phase 1 BEVZ92 bevacizumab biosimilar bioequivalence trial versus Avastin in first-line metastatic colorectal cancer completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• BEVZ92 (bevacizumab biosimilar)

Snippet

Sponsor: mAbxience Research S.L. | Conditions: Metastatic Colorectal Cancer (mCRC) | Phase 1 | Status: COMPLETED | Results posted: 2019-07-23